Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

184.02 +2.34 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira. 
Via Stocktwits
Topics World Trade
Exposures Tariff
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio. 
Via MarketBeat
AbbVie Jumps After Hiking Its Outlook On The Back Of Strong Immunology Sales
The company also raised its outlook for 2025, though noted that guidance hike doesn't include potential pharma sector tariffs. 
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
AbbVie (NYSE:ABBV) Reports Bullish Q1
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
A Glimpse of AbbVie's Earnings Potential
Via Benzinga
Analyst Expectations For AbbVie's Future
Via Benzinga
Is the Market Bullish or Bearish on AbbVie?
Via Benzinga
US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says 'This Isn't Stuff You See In Bear Market'
U.S. stock futures continued to rise on Friday, following a three-day back-to-back winning streak in the regular session, amid growing earnings optimism and the easing of trade tensions between the... 
Via Benzinga
Topics World Trade
Exposures Tariff
Earnings Scheduled For April 25, 2025
Via Benzinga
US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher
U.S. stock futures are up Thursday night following three back-to-back days in the green during the regular session, amid growing earnings optimism and easing trade tensions. 
Via Benzinga
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'
Via Benzinga
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
Exposures COVID-19 Pension
AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now
Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
This StoneCo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Is AbbVie Stock a Buy?
The pharmaceutical giant has been a roller coaster over the past several months. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
Exposures Intellectual Property Political Tariff
A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'
Via Benzinga
After The Tariff Flush, A Fresh Look At AbbVie Pharma
If ABBV has truly made a bottom, we should see it clear and close over 182. 
Via Talk Markets
Topics Stocks / Equities
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades'
Via Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.